Opus Genetics is a Durham clinical-stage ophthalmology company whose equity now prices a funded rare-retina gene-therapy platform rather than the leftover small-molecule story that entered the public markets through the Ocuphire combination, and the live debate is whether two early inherited-retinal signals plus a partnered pupil-reversal drop can support that recapitalized multiple before either program produces a controlled dataset.
On September 9 the company reported that every participant in the low-dose BEST1 opening cohort showed a clinically meaningful gain on at least one functional vision test after a single subretinal injection of OPGx-BEST1, the experimental gene therapy designed to restore a working copy of the BEST1 gene inside the retinal pigment epithelium, the support layer that keeps photoreceptors alive. That result is the first human evidence that the vector can move both function and structure in Best disease, a condition that currently has no approved disease-modifying treatment, and the Food and Drug Administration later aligned on a potential pivotal yardstick of a 3 decibel microperimetry gain at 5 or more mapped loci paired with a patient-reported outcome. The mechanism that matters for holders is not the headline that the whole opening cohort improved; it is that the gains clustered in patients who still had remaining photoreceptors and that an independent monitor cleared a threefold dose increase, which is how a tiny open-label signal either becomes a registrational design or dies as an uncontrolled anecdote.
The tension is that the same recapitalization that bought a stated cash runway into 2029 also stacked a secured note, a large warrant liability, and a still-thin collaboration line on top of a company that employs fewer than 30 people and is trying to run multiple first-in-human programs at once. License revenue in the June quarter fell to $0.8 million as Viatris reimbursement for phentolamine development rolled off, while research spending nearly doubled as manufacturing and inherited-retinal trials ramped. A holder who treats the mid-year cash pile as a valuation floor is ignoring both the Oberland claim and the fact that gene-therapy cash is option fuel that disappears the moment a higher-dose cohort or a registrational run-in goes wrong.
The next facts that resolve the file are the higher-dose BEST1 cohort, LCA5 registrational dosing, and the October presbyopia decision on the partnered drop. Those three items decide whether Opus is a multi-program rare-retina company that happened to own a royalty or a recapitalized option book still waiting on a controlled trial.